NCT00694057View on ClinicalTrials.gov

Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

HE3286

HE3286 10 mg per day (5 mg BID)

DRUG

Placebo

Placebo capsules BID

Trial Locations (22)

53142

Kenosha

60616

Chicago

63141

St Louis

70808

Baton Rouge

78229

San Antonio

79905

El Paso

84107

Salt Lake City

89106

Las Vegas

89148

Las Vegas

90057

Los Angeles

90211

Beverly Hills

90255

Huntington Park

90620

Buena Park

90806

Long Beach

91505

Burbank

91950

National City

92025

Escondido

92801

Anaheim

92805

Anaheim

93726

Fresno

95608

Carmichael

95661

Roseville

Sponsors
All Listed Sponsors
lead

Harbor Therapeutics

INDUSTRY